HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial...

68
HIGHLIGTS: Focus on GLP-1 analogues Καλλιόπη Κώτσα Επικ. Καθηγήτρια Ενδοκρινολογίας-Διαβητολογίας ΑΠΘ

Transcript of HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial...

Page 1: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p

HIGHLIGTS: Focus on GLP-1 analogues

Καλλιόπη Κώτσα

Επικ. Καθηγήτρια Ενδοκρινολογίας-Διαβητολογίας ΑΠΘ

Page 2: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 3: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 4: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 5: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 6: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 7: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 8: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 9: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 10: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 11: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 12: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 13: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 14: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 15: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 16: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 17: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 18: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 19: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 20: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 21: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 22: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 23: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 24: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 25: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 26: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 27: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 28: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 29: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 30: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 31: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 32: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 33: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 34: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 35: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 36: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 37: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 38: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 39: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 40: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 41: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 42: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 43: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 44: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 45: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 46: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 47: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 48: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 49: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 50: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 51: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 52: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 53: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 54: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 55: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 56: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 57: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 58: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 59: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 60: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 61: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 62: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 63: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 64: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 65: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 66: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 67: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p
Page 68: HIGHLIGTS: Focus on GLP-1 analogues · Καλλιόπη Κώ 2α ... CV death, non-fatal myocardial infarction or non-fatal stroke Placebo Liraglutide HR: 0.87 Cl (0.78-0.97) p

orderalpha: non-parametric order- Efficiency Analysis for Stata · 2011. 7. 19. · Measuring Efficiency Parametric vs. Non-Parametric Approaches Non-Parametric Approaches 1.Data

orderalpha: non-parametric order- Efficiency Analysis for Stata · 2011. 7. 19. · Measuring Efficiency Parametric vs. Non-Parametric Approaches Non-Parametric Approaches 1.Data

040 Non Metallic Pump - alphadynamic.eu

040 Non Metallic Pump - alphadynamic.eu

Variable Clinical Phenotypes of -Thalassemia Syndromesdownloads.hindawi.com/journals/tswj/2009/529605.pdf · thalassemia major, generally considered fatal, have been reported. It

Variable Clinical Phenotypes of -Thalassemia Syndromesdownloads.hindawi.com/journals/tswj/2009/529605.pdf · thalassemia major, generally considered fatal, have been reported. It

FATAL AZARD PROTOCOLS - Queensland Coal Mining Board of ...

FATAL AZARD PROTOCOLS - Queensland Coal Mining Board of ...

Expo Asma Fatal Uci

Expo Asma Fatal Uci

Non-intersection of transient branching random walks · ProbabilityTheoryandRelatedFields Non-intersectionoftransientbranchingrandomwalks Tom Hutchcroft1 Received:7October2019 ...

Non-intersection of transient branching random walks · ProbabilityTheoryandRelatedFields Non-intersectionoftransientbranchingrandomwalks Tom Hutchcroft1 Received:7October2019 ...

INTRODUCTION - IPF€¦ · INTRODUCTION - IPF Idiopathic pulmonary fibrosis (IPF) is a disease that has an aggressive course and is usually fatal an average of 3 to 6 years after

INTRODUCTION - IPF€¦ · INTRODUCTION - IPF Idiopathic pulmonary fibrosis (IPF) is a disease that has an aggressive course and is usually fatal an average of 3 to 6 years after

orderalpha: non-parametric order- Efficiency Analysis for ...fm · Measuring Efficiency Parametric vs. Non-Parametric Approaches Non-Parametric Approaches 1.Data envelopment Analysis

orderalpha: non-parametric order- Efficiency Analysis for ...fm · Measuring Efficiency Parametric vs. Non-Parametric Approaches Non-Parametric Approaches 1.Data envelopment Analysis

N-channel 600 V, 0.78 typ., 6 A MDmesh DM2 Power MOSFET in ... · N-channel 600 V, 0.78 Ω typ., 6 A MDmesh™ DM2 Power MOSFET in a TO-220FP package Datasheet - production data Figure

N-channel 600 V, 0.78 typ., 6 A MDmesh DM2 Power MOSFET in ... · N-channel 600 V, 0.78 Ω typ., 6 A MDmesh™ DM2 Power MOSFET in a TO-220FP package Datasheet - production data Figure

B'Tselem Report: Take No Prisoners - The Fatal Shooting of …€¦ · 1 miieay migwel `l mipihqlt ly mzbixd oeghiad zegek iyp` ixin "mixvrn irvan" jldna 2005 i`n ,rcin sc ןמרדיינש

B'Tselem Report: Take No Prisoners - The Fatal Shooting of …€¦ · 1 miieay migwel `l mipihqlt ly mzbixd oeghiad zegek iyp` ixin "mixvrn irvan" jldna 2005 i`n ,rcin sc ןמרדיינש

Simulation of Non-Equilibrium Flows

Simulation of Non-Equilibrium Flows

monogamy of non-signalling correlations

monogamy of non-signalling correlations

0 v recourse.uoi.gr/pluginfile.php/89813/mod_resource/content...– “the small pox, so fatal, so general among us, is entirely harmless here by the invention of ingrafting… M.

0 v recourse.uoi.gr/pluginfile.php/89813/mod_resource/content...– “the small pox, so fatal, so general among us, is entirely harmless here by the invention of ingrafting… M.

Bahan ajar stat non par

Bahan ajar stat non par

Variable Clinical Phenotypes of -Thalassemia Syndromes · 2019. 7. 31. · serious and frequently fatal of the α-thalassemia syndromes is that of the four gene–deletion syndrome,

Variable Clinical Phenotypes of -Thalassemia Syndromes · 2019. 7. 31. · serious and frequently fatal of the α-thalassemia syndromes is that of the four gene–deletion syndrome,

Non renewable energy

Non renewable energy

Non-parametrische Testverfahren

Non-parametrische Testverfahren

Non – Parametric Statistics

Non – Parametric Statistics

MEMPHYS non-oscillation physics

MEMPHYS non-oscillation physics

Non ferrous alloy

Non ferrous alloy